One-Shot CRISPR treatment aims to free patients from lifelong blood transfusions
NCT ID NCT05577312
Summary
This early-stage study is testing a single infusion of a patient's own genetically modified stem cells to treat severe beta-thalassemia. The therapy uses CRISPR gene editing technology with the goal of helping the body produce healthy red blood cells. If successful, it could reduce or eliminate the need for regular blood transfusions in people with this serious inherited blood disorder.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
-
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, 510510, China
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
-
Xiangya Hospital of Central South University
Changsha, Hunan, 510510, China
Conditions
Explore the condition pages connected to this study.